Free Trial

Co-Diagnostics Q3 2023 Earnings Report

Co-Diagnostics logo
$0.73 +0.00 (+0.66%)
(As of 12/20/2024 05:16 PM ET)

Co-Diagnostics EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Co-Diagnostics Revenue Results

Actual Revenue
$2.46 million
Expected Revenue
$0.20 million
Beat/Miss
Beat by +$2.26 million
YoY Revenue Growth
N/A

Co-Diagnostics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Co-Diagnostics Earnings Headlines

Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Co-Diagnostics Reports Q3 2024 Financial Results
See More Co-Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Co-Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Co-Diagnostics and other key companies, straight to your email.

About Co-Diagnostics

Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

View Co-Diagnostics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings